Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818. 

Pikavation is a wholly-owned subsidiary of Synnovation.  SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase I/II clinical trials for the treatment of HR+/HER2- metastatic breast cancer and other solid tumours. 

“We believe Novartis’s global capabilities and commitment to patients with cancer will accelerate the development of SNV4818 for patients with PI3Kα mutation–driven solid tumours beyond what Synnovation could achieve alone,” said Wenqing Yao, Chief Executive Officer of Synnovation. “This acquisition reflects the strength of the Synnovation team and our drug discovery and development capabilities. We will continue advancing other promising programmes in our R&D pipeline, including our selective PARP1 inhibitor, SNV1521, as well as additional oncology and immunology projects.” 

Under the terms of the agreement, Novartis will pay Synnovation $2 billion upfront in cash, and up to $1 billion in development, regulatory, and commercial milestones. The transaction is expected to be finalised in the first half of 2026. 

Novartis will be solely responsible for future development and commercialisation of SNV4818 and other PI3Kα inhibitor programmes and Synnovation will continue operating as an independent entity. 

The post Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion appeared first on Drug Discovery World (DDW).